Home / Healthcare/ GSK’s new triple lung drug beats other modern inhalers in study

GSK’s new triple lung drug beats other modern inhalers in study


Comments / {{hitsCtrl.values.hits}} Views / Wednesday, 27 September 2017 00:00


London (Reuters): GlaxoSmithKline produced clinical data on Wednesday showing its newly approved three-in-one inhaler reduced life-threatening attacks in chronic obstructive pulmonary disease (COPD) patients more than other modern treatments.

Britain’s biggest drugmaker believes the results confirm the potential of the once-daily single inhaler, Trelegy Ellipta, a product it hopes will offset the impact of generic competition to the older lung drug Advair.

Trelegy won approval based on clinical tests showing it improved lung function and exacerbations more than AstraZeneca’s long-established two-drug inhaler Symbicort, which works in a similar way to Advair.

The latest clinical trial, however, compares Trelegy to two more modern two-drug combinations and was seen as a more critical test for doctors wanting to know if the new product really delivers an added benefit.

The IMPACT study, which involved 10,355 patients, showed Trelegy delivered statistically significant reductions in the rate of annual exacerbations, or attacks, compared with both Breo and Anoro, two other relatively new GSK medicines.

GSK and its partner Innoviva plan to submit the latest data from the so-called IMPACT trial to regulatory authorities from the second quarter of 2018, with the aim of expanding the indicated patient population for Trelegy.


Share This Article


COMMENTS

Today's Columnists

Why are farmers not utilising their lands and watching them go to waste despite Government efforts?

Thursday, 14 December 2017

Ramanathan (not his real name), a land owner, received a letter from the Govi Jana Sevaya, stating that his fields and some bare lands have not been cultivated for several years.


Betrayal of a Bodhisattva

Thursday, 14 December 2017

‘Koley iragena angey halaganta epa. Londery hathakinn suddda karanta behe’ is the advice in pithy Sinhala idiom, the President offered to his critics and opponents in a recent homily delivered at Nikaweratiya.


India-Sri Lanka economic relations in Modi’s India

Thursday, 14 December 2017

The relationship between Sri Lanka and India has always been characterised by surprises, setbacks and progress, and the three years of the Modi Government in India have not been an exception


Kodak moments for Sri Lanka Tourism

Wednesday, 13 December 2017

It was quite disheartening to see the tourism numbers for November 2017 dropping to 167,511 visitors at 0.2% growth against


Columnists More